Fresenius (FRE) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
25 Feb, 2026Executive summary
Achieved strong organic revenue growth of 7% year-over-year for FY 2025, with Q4 organic revenue up 9% and EBIT up 13% at constant currency, driven by both Fresenius Kabi and Fresenius Helios.
Core EPS grew double digits for the second consecutive year, reaching €2.87 for FY 2025 (+12%), with Q4 Core EPS up 16%.
Transformation strategy (#FutureFresenius, Rejuvenate) and digital initiatives drove momentum, making the company leaner, more resilient, and innovation-focused.
Net debt/EBITDA improved to 2.7x, reflecting strong cash flow and debt reduction, well within the target corridor.
Dividend proposal of €1.05 per share, a 5% increase year-over-year, with a payout ratio of 37%.
Financial highlights
FY 2025 group revenue: €22,554 million (+7% organic growth); Q4 revenue: €5,875 million (+9% organic growth).
FY 2025 group EBIT: €2,595 million (+6% constant currency); Q4 EBIT: €713 million (+13% constant currency).
FY 2025 Core EPS: €2.87 (+12% constant currency); Q4 Core EPS: €0.78 (+16% constant currency).
Operating cash flow in Q4: €1,340 million (+36% year-over-year); FY 2025: €2,606 million (+5%).
Free cash flow in Q4: €966 million (+67% year-over-year); FY 2025: €1,285 million (-23%).
Outlook and guidance
FY 2026 guidance: organic revenue growth of 4–7%, constant currency Core EPS growth of 5–10%, EBIT margin ~11.5%.
Fresenius Kabi: organic revenue growth in mid- to high-single digits, EBIT margin 16.5–17.0%.
Fresenius Helios: organic revenue growth in mid-single digits, EBIT margin 10.0–10.5%.
Structural EBIT margin ambition for Kabi raised to 17–19%.
Guidance reflects ongoing macroeconomic and geopolitical volatility; potential impacts from recent US Supreme Court ruling not yet assessed.
Latest events from Fresenius
- Resilient global healthcare group posts solid Q2 2020 results, navigating COVID-19 challenges.FRE
Berenberg & Goldman Sachs 9th German Corporate Conference presentation11 Feb 2026 - Solid sales growth in Q2 2022 offset by profit declines amid labor and inflation headwinds.FRE
Morgan Stanley 20th Annual Global Healthcare Conference presentation11 Feb 2026 - Q1/24 delivered strong growth, outlook raised, and portfolio streamlined for higher quality earnings.FRE
Stifel European Healthcare Summit presentation11 Feb 2026 - Raised 2024 outlook with strong growth in pharma and hospital operations, emphasizing efficiency.FRE
SdK Anlegerforum presentation11 Feb 2026 - Q2/24 delivered robust growth, margin expansion, and accelerated transformation progress.FRE
Berenberg Seminar presentation11 Feb 2026 - Q3/24 delivered robust growth, margin expansion, and an upgraded FY/24 outlook.FRE
Berenberg European Conference presentation11 Feb 2026 - Transformation, innovation, and biosimilars drive growth and margin expansion.FRE
43rd Annual J.P. Morgan Healthcare Conference11 Feb 2026 - REJUVENATE phase accelerates growth, governance, and sustainability with strong financial momentum.FRE
Corporate Governance Roadshow presentation11 Feb 2026 - Q3/25 saw 6% organic revenue growth, 14% EPS rise, and upgraded FY25 guidance.FRE
Investor presentation11 Feb 2026